English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduResearchers examined the material properties of a thin surface barrier called the glycocalyx with unprecedented resolution, revealing information that could help improve current cell-based cancer immunotherapies.
Tag: Immunotherapy
Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).
A Potential New Target for Head and Neck Cancer Immunotherapy
UC San Diego researchers have identified a strong association between the product of a gene expressed in most cancers and elevated levels of white blood cells that produce antibodies within tumors, suggesting a new therapeutic target.
MD Anderson Research Highlights for March 8, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
UChicago Medicine-led team selected for the 2022 Michael & Lori Milken Family Foundation-PCF Challenge Award to develop novel immunotherapy approaches in advanced prostate cancer
The Prostate Cancer Foundation (PCF) has awarded a $1 million grant to a renowned specialist at the University of Chicago Medicine Comprehensive Cancer Center.
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
Immunotherapy After Surgery Provides Significant, Durable Benefit for High-Risk Bladder Patients
Immunotherapy after surgery increased bladder cancer patients’ chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2023 Genitourinary Cancers Symposium in February.
Immunaeon Joins the RegenMed Hub
Immunaeon is the latest addition to the RegeneratOR’s Innovation AcceleratOR, located in the Regenerative Medicine Hub (RegenMed Hub), a rapidly growing regenerative medicine ecosystem based in the Innovation Quarter of Winston-Salem.
MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers
MD Anderson and Federation Bio announced a strategic collaboration to design and manufacture a synthetic microbial consortium with the goal of improving responses in immunotherapy-resistant cancers.
Tumor microbiome linked to immunotherapy success in sarcoma patients
A new UC Davis study reveals the interaction between tumor microbiome and the immune system may be the secret to improving outcomes for sarcoma patients.
‘Hard to Lose’ Mutations in Tumors May Predict Response to Immunotherapy
Investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that a subset of mutations within the overall TMB, termed “persistent mutations,” are less likely to be edited out as cancer evolves, rendering tumors continuously visible to the immune system and predisposing them to respond to immunotherapy.
Using A Seaweed Sugar to Trigger Immune Responses That Suppress Melanomas
Moffitt Cancer Center researchers, led by cancer biologist Eric Lau, Ph.D., have identified a relatively natural way to increase the numbers and antitumor activities of TILs. In a new article published in Nature Cancer, Lau’s team demonstrates how L-fucose, a nontoxic dietary plant sugar that is enriched in red and brown seaweeds, can increase TILs, promote antitumor immunity and improve the efficacy of immunotherapy.
Immunotherapy with two novel drugs shows activity in colorectal cancer
A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, according to a Dana-Farber Cancer Institute researcher.
Certain gene signaling rewires tumors after immunotherapy
Researchers from the University of Michigan Rogel Cancer Center have found a mechanism for why a subset of patients’ tumors grow, rather than shrink, when faced with immunotherapy.
Surgery First for Colon Cancer? Not So Fast, According to New Study in JNCCN
New research in JNCCN finds that immunotherapy from immune checkpoint (PD-1) inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).
MD Anderson Research Highlights for January 11, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Novel T cell receptor therapy shows early anti-tumor activity
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Study discovers triple immunotherapy combination as possible treatment for pancreatic cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment (TIME) and significantly improved anti-tumor responses in preclinical models of pancreatic cancer.
MD Anderson Research Highlights for December 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a cell cycle checkpoint inhibitor with potential therapeutic effects in an ovarian cancer subtype, a telementoring program for French-speaking oncology providers in Africa, insights into the relationship between obesity and immunotherapy side effects, updates to the world’s largest cancer drug discovery knowledgebase, improvements to treatment response by blocking the EGFR pathway, and a novel noninvasive diagnostic test for immunotherapy-related kidney injury.
Immunotherapy eliminates disease-causing cells in mice with MS-like disease
Researchers at Washington University School of Medicine in St. Louis have shown that the cancer therapy known as CAR-T can be applied to multiple sclerosis (MS), an autoimmune disease of the nervous system. The findings extend the powerful tool of immunotherapy to autoimmune diseases, a class of diseases that are often debilitating and difficult to treat.
MD Anderson Research Highlights for November 30, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Simultaneous radiation and immunotherapy are beneficial for a subset of lung cancer patients
In a recently published Nature Cancer paper, UChicago Medicine researchers have identified the first biomarker – aneuploidy – that predicts response to the radiation therapy and immune checkpoint blockade treatment combination.
Biomarker Predicts Resistance to Immunotherapies in Melanoma
Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.
New study brings personalized immunotherapy prescriptions a step closer
In a step likely to advance personalised cancer treatment, scientists have for the first time shown in patients that levels of biomarkers are not enough to tell which patients are likely to respond best to immunotherapy.
Andrew Sabin Family Foundation doubles down on commitment to end cancer with $10M gift
The University of Texas MD Anderson Cancer Center today announced a $10 million gift to the James P. Allison Institute from the Andrew Sabin Family Foundation and Andrew “Andy” Sabin, a senior member of the MD Anderson Cancer Center Board of Visitors (BOV). The gift is the philanthropist’s second multimillion-dollar commitment to MD Anderson in less than 10 years.
Albert Einstein College of Medicine Researchers Develop Promising New Cancer Therapy
Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system’s T cells to attack tumor cells. Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement. In a paper published online today in The Journal of Clinical Investigation (JCI), scientists at Albert Einstein College of Medicine describe findings that could bolster the effectiveness of immune-checkpoint therapy.
MD Anderson Research Highlights: SITC 2022 Special Edition
This special edition features upcoming presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, including immunotherapy advances in human papillomavirus (HPV)-positive head and neck cancers, microbiome signatures linked with specialized immune-cell clusters, and promising early activity from novel immunotherapy drugs in advanced melanoma and colorectal cancer.
MD Anderson Research Highlights for November 3, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Hormone therapy could lower risk of immunotherapy-associated myocarditis in women
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco (UCSF) has discovered the underlying cause of gender differences in immunotherapy-associated myocarditis after immune checkpoint inhibitor (ICI) treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.
CANCER RESEARCH INSTITUTE TO HOST ANNUAL VIRTUAL IMMUNOTHERAPY PATIENT SUMMIT ON NOVEMBER 11-12, 2022
Free online event for cancer patients and caregivers featuring immunotherapy experts and patient advocates taking place Nov. 11-12, 2022.
Allison Institute establishes internal advisory council of MD Anderson experts
MD Anderson’s James P. Allison institute today announced the establishment of its internal advisory council to provide scientific input and to align the work of the institute with the broader MD Anderson research enterprise.
Study Offers New Hope for Treatment-Resistant Prostate Cancer
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that they can circumvent a key mechanism in castration-resistant prostate cancer (CRPC) and possibly make immunotherapies more effective. By infusing nitric oxide (NO) into animal models, the team shrank tumors and paved the way for potential combination therapies. The study was published in Nature Cell Death & Disease.
FSU faculty available to speak for Breast Cancer Awareness Month
By: Bill Wellock | Published: October 10, 2022 | 1:11 pm | SHARE: More than 264,000 people are diagnosed with breast cancer every year in the United States. Although deaths from breast cancer have declined over time, it remains the second-leading cause of cancer death among women.October is Breast Cancer Awareness Month, an opportunity to focus on the impact of this disease.
Cedars-Sinai Cancer Welcomes Nine Oncologists to Its Affiliate, Huntington Cancer Center
Cedars-Sinai Cancer is welcoming nine oncology specialists to its affiliate, Huntington Cancer Center. The cancer specialists will be based at Huntington’s Pasadena campus, making it easier for San Gabriel Valley residents to access Cedars-Sinai Cancer clinical trials and innovative treatment options.
Advanced Melanoma Survival Improves Significantly When Immunotherapy is Given Before Targeted Therapy
A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72 percent survival rate) versus those who initially got targeted therapies (52 percent survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.
New collaborative study to investigate sequential combinations of targeted inhibitors and immunotherapies against cancer
The National Cancer Institute has awarded a five-year, $13.3 million grant to a collaborative study on sequential combinations of targeted inhibitors and immunotherapies against cancer.
MD Anderson Research Highlights: ESMO 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features upcoming oral presentations by MD Anderson researchers at the European Society for Medical Oncology (ESMO) Congress 2022 focused on clinical advances across a variety of cancer types. Highlights include promising early data from a novel T cell therapy for solid tumors, targeted therapy progress in rare and advanced cancers, biomarkers of immunotherapy response, and features associated with clinical outcomes in leptomeningeal disease. More information on ESMO content from MD Anderson can be found at MDAnderson.org/ESMO.
MD Anderson and Virogin Biotech announce strategic collaboration to accelerate oncolytic virus research and development for treating advanced cancers
MD Anderson and Virogin Biotech today announced a strategic collaboration to accelerate the development of oncolytic virus therapies for advanced cancers.
UCSF-Led Research Team Reveals Mechanisms at Work in Progression of Pancreatic Cysts to Cancer
A UC San Francisco-led team of international researchers has outlined the comprehensive immune landscape and microbiome of pancreatic cysts as they progress from benign cysts to pancreatic cancer. Their findings, publishing August 31 in Lancet Gastroenterology and Hepatology, could reveal the mechanism of neoplastic progression and provide targets for immunotherapy to inhibit progression or treat invasive disease.
Immunotherapy Covered in Special Edition of Current Clinical Pathology
In the latest Current Clinical Pathology publication on Immunotherapy, Sbarro Health Research Organization (SHRO) President, Antonio Giordano, M.D., Ph.D., co-edits the volume, focused on cardiovascular toxicities.
Genetics May Predict Bladder Cancer Immunotherapy Response
Investigators from Cedars-Sinai Cancer have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy. Their results, published today in the peer-reviewed Journal of the National Cancer Institute, could one day help guide clinicians to the most effective treatments for cancer patients.
WFIRM researchers create specific cancer organoid system to study bacterial effects on immunotherapy
Wake Forest Institute for Regenerative Medicine (WFIRM) researchers are using a tumor organoid system to examine the effects of metabolites secreted by bacteria on a specialized immunotherapy – immune checkpoint blockage, a promising cancer treatment development – to determine why some patients don’t respond or develop a resistance to the treatment over time.
MD Anderson Research Highlights for July 27, 2022
Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients with lateral pelvic lymph node metastases in rectal cancer. Laboratory findings offer new understanding of the pancreatic cancer immune microenvironment, melanoma cell states, TP53 mutation status in acute myeloid leukemia (AML), and potential targets for metastatic prostate cancer and GNAS-mutant colorectal cancer.
Moffitt Researchers Use Mathematical Modeling to Explain Immunotherapy Responses
In a new article published in the Journal for ImmunoTherapy of Cancer, Moffitt Cancer Center researchers demonstrate how mathematical modeling can be used to analyze the impact of different cancer treatments on tumor and immune cell dynamics and help predict outcomes to therapy and personalize cancer treatment.
MD Anderson Research Highlights for July 13, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targets involved in protecting DNA replication forks and preventing inflammatory responses, a new treatment option for elderly patients with late-stage acute myeloid leukemia, insights into the breast cancer tumor microenvironment, biomarkers of response to targeted and immune therapies, a novel cellular therapy option for osteosarcoma and a new target for inducing ferroptosis in cancer cells.
Chemo-Radio-Immunotherapy Treats Local Cancers, Minimizes Side Effects
In a study published July 5, 2022, researchers at University of California San Diego School of Medicine present a three-prong approach to targeting local cancers while minimizing adverse effects in other parts of the body. The precision cancer therapy combines…
MD Anderson Research Highlights for June 29, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a lower-intensity therapy for acute myeloid leukemia, a new target for treating chronic myelomonocytic leukemia, real-world synthetic controls for clinical trials in rare cancers, a potential biomarker to predict endocrine therapy response in breast cancer, integrated CRISPR screens to identify novel tumor suppressors, and a deeper knowledge of the immune tumor microenvironment in melanoma-derived brain metastases.
The Mark Foundation for Cancer Research Expands Partnership with The Johns Hopkins University to Accelerate Groundbreaking Immunotherapy Research
The Mark Foundation for Cancer Research and the Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) announced today a new $10 million commitment at The Johns Hopkins University to fund novel work and advance immunotherapy research to provide lifesaving breakthroughs to people with cancer.
MD Anderson and Turning Point Therapeutics announce strategic alliance to advance precision cancer therapies
MD Anderson and Turning Point Therapeutics announced a strategic research and development alliance to evaluate Turning Points investigational targeted therapies against ROS1, NTRK, MET and other cancer drivers.
Pushing T cells down “memory lane” may improve cancer therapy
Scientists at St. Jude Children’s Research Hospital identified proteins that help decide T cell fate and used the finding to improve CAR-T cell therapy in a solid tumor model.